Compare INLX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | EVAX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 42.7M |
| IPO Year | N/A | 2021 |
| Metric | INLX | EVAX |
|---|---|---|
| Price | $8.25 | $5.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 2.6K | ★ 100.4K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,539,674.00 | $7,650,000.00 |
| Revenue This Year | N/A | $128.77 |
| Revenue Next Year | $15.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 132.17 |
| 52 Week Low | $8.37 | $1.20 |
| 52 Week High | $15.72 | $12.15 |
| Indicator | INLX | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 31.87 | 50.34 |
| Support Level | $8.40 | $6.15 |
| Resistance Level | $8.53 | $6.70 |
| Average True Range (ATR) | 0.12 | 0.51 |
| MACD | 0.05 | 0.08 |
| Stochastic Oscillator | 10.48 | 41.88 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.